Log In
Print this Print this

Faslodex, fulvestrant

Also known as: ICI 182,780

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionSelective estrogen receptor down-regulator (SERD)
Molecular Target Estrogen receptor (ESR1)
Mechanism of ActionEstrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBreast cancer
Indication DetailsTreat advanced breast cancer in postmenopausal women who had disease progression following aromatase inhibitor (AI) therapy; Treat advanced or metastatic postmenopausal breast cancer; Treat first line advanced breast cancer; Treat hormone receptor-positive metastatic breast cancer; Treat hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer whose cancer has progressed after endocrine therapy; Treat postmenopausal women with estrogen receptor-positive, locally advanced or metastatic breast cancer; Treat progressed or recurrent advanced breast cancer in postmenopausal women; Treat treatment-naïve postmenopausal women with hormone receptor-positive metastatic breast cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today